Short answer
Vera Therapeutics, Inc. (VERA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$121M
- −134.1% YoY
- EPS (diluted)
- −$1.69
- −108.6% YoY
Source: XBRL data from the Vera Therapeutics, Inc. (VERA) Q1 2026 10-Q on SEC EDGAR. USD.
Vera Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New-trigger risk unclear; provided excerpt lacks comparison with the most recent 10-K and ends mid-section
- Liquidity risk: $596.8 million in cash, equivalents and marketable securities expected to fund operations beyond 12 months
- Debt covenant risk: $75.0 million outstanding under the 2025 Loan Agreement, with borrowing capacity up to $500.0 million
- Regulatory risk: FDA-required additional trials or nonclinical studies could increase development costs and delay approval
- Clinical execution risk: prior atacicept Phase 2 SLE trial missed its primary endpoint in the overall population
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.